Market Cap : 7.44 B | Enterprise Value : 6.39 B | PE Ratio : | PB Ratio : 8.77 |
---|
NAS:IONS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:IONS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-Revenue measures a company's ability to pay off its debt.
Ionis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $300.5 Mil. Ionis Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $539.1 Mil. Ionis Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2020 was $1,161.1 Mil. Ionis Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2020 was 0.72.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Ionis Pharmaceuticals's Debt-to-Revenue falls into.
Debt-to-Revenue measures a company's ability to pay off its debt.
Ionis Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (300.462 | + | 539.112) | / | 729.264 | |
= | 1.15 |
Ionis Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2020 is calculated as
Debt-to-Revenue | = | Total Debt | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (300.462 | + | 539.112) | / | 1161.124 | |
= | 0.72 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2020) Revenue data.
No Headline